Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China · Delayed Price · Currency is CNY 19.05
+0.07 (0.37%)
Sep 14, 2026, 3:04 PM CST
SHE:300357 Revenue
Zhejiang Wolwo Bio-Pharmaceutical had revenue of 261.32M CNY in the quarter ending June 30, 2026, with 2.17% growth. This brings the company's revenue in the last twelve months to 1.09B, up 11.42% year-over-year. In the year 2025, Zhejiang Wolwo Bio-Pharmaceutical had annual revenue of 1.06B with 14.81% growth.
Revenue (ttm)
1.09B
Revenue Growth
+11.42%
P/S Ratio
9.10
Revenue / Employee
604.17K
Employees
1,808
Market Cap
9.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.06B | 137.01M | 14.81% |
| Dec 31, 2024 | 925.39M | 77.20M | 9.10% |
| Dec 31, 2023 | 848.19M | -47.83M | -5.34% |
| Jan 1, 2023 | 896.02M | 88.32M | 10.94% |
| Dec 31, 2021 | 807.69M | 171.48M | 26.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.82B |
| Zhejiang Int'l Group | 34.20B |
| Yifan Pharmaceutical | 4.97B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.21B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Shanghai InnoStar Bio-tech | 901.08M |
| Chongqing Lummy Pharmaceutical | 748.94M |
| Hangzhou Bio-Sincerity Pharma-Tech | 709.72M |